Patent intelligence · US
US 11701394
Compositions and methods for treating cholestatic disease
Compositions and methods for treating cholestatic disease
Patent details — US 11701394
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 18, 2023
- Expiration
- Jul 13, 2043
- Applicant
- Seres Therapeutics, Inc.
- Claims
- 17
- CPC classes
- A61K, A61K31/58, A61K35/74, A61K35/745
Quick answer
US 11701394 (Compositions and methods for treating cholestatic disease) is held by Seres Therapeutics, Inc.. Status: granted. Granted Jul 18, 2023. Expires Jul 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Seres Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/58, A61K35/74, A61K35/745, A61P, A61P1/16
More from Seres Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12409197
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 12214002
Compositions and methods for treating antibiotic resistance
granted -
US 12083151
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 11918612
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 11730775
Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof
granted -
US 11666612
Network-based microbial compositions and methods
granted -
US 11464812
Synergistic bacterial compositions and methods of production and use thereof
granted
Frequently asked questions
What is US patent 11701394?
US 11701394 (Compositions and methods for treating cholestatic disease) is held by Seres Therapeutics, Inc.. Status: granted. Granted Jul 18, 2023. Expires Jul 13, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11701394?
Seres Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.
When does US 11701394 expire?
Our index shows an expiration date of Jul 13, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.